View Post

BARD1 Life Sciences (ASX:BD1) receives positive results from breast cancer study

In Clinical Studies News by Barbara Jacoby

By: Julia Seymour From: BARD1 Life Sciences (BD1) has received results from a preliminary study demonstrating the feasibility of using SubB2M in an immunohistochemistry (IHC) application for breast cancer tissue The study compared cancer tissue from an invasive ductual breast cancer tumour biopsy to a non-cancer breast tissue biopsy The study also demonstrated that the SubB2M IHC test could …